

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):
April 22, 2005

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Commission File No. 0-21116

Utah 87-0500306

(State or other jurisdiction of (IRS Employer Identification
incorporation) Number)

3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On April 22, 2005, USANA Health Sciences, Inc. issued a press release announcing an increase in the authorized dollar amount for additional repurchases of the Company's common stock from \$4.1 million to \$10 million. The release also announced that share repurchases will be made from time-to-time, in the open market, through block trades or otherwise, and will be funded with internally generated cash. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The company will also post this document on its corporate website,

www.usanahealthsciences.com, under the "investors" link.

Item 9.01 Financial Statements and Exhibits (furnished herewith)

(c) Exhibits

Exhibit 99.1 Press release issued by USANA Health Sciences, Inc. dated
April 22, 2005

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller

Gilbert A. Fuller, Chief Financial Officer

Date: April 25, 2005

3

USANA Board Authorizes \$10 Million Share Repurchase Plan

SALT LAKE CITY--(BUSINESS WIRE)--April 22, 2005--USANA Health Sciences, Inc. (Nasdaq:USNA) today announced that its board of directors has increased the authorized dollar amount for additional repurchases of its outstanding shares of common stock from \$4.1 million to \$10.0 million.

The share repurchase will be made from time-to-time, in the open market, through block trades or otherwise, and will be funded with internally generated cash.

Prior to this authorization, USANA had approximately \$4.1 million remaining in its share repurchase plan, which was announced in November 2004. During 2004, the Company repurchased a total of 1.2 million shares for a total investment of \$34.9 million or an average of \$29.02 per share.

USANA had 19,162,528 common shares outstanding as of April 2, 2005.

About USANA

USANA develops and manufactures high quality nutritional and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, the Netherlands, and the United Kingdom. More information on USANA can be found at <http://www.usanahealthsciences.com>.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, and uncertainties associated with our planned international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

CONTACT: USANA Health Sciences, Inc.

Investor Relations Manager

Riley Timmer, 801-954-7100

investor.relations@us.usana.com